Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products
Genes · 2024-04-08 · 15 (4) · 468
DOI: 10.3390/genes15040468 ↗At a glance
Übersichtsarbeit in Genes, published online on 2024-04-08. Written by Yalan Zhou and 4 co-authors. Institution: Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Major MEDLINE topics: Precision Medicine, Biological Products, Neoplasms, Antineoplastic Agents. Cited 46 times so far (Crossref); 159 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine, Shanghai Municipal Health Commission.
Abstract (original language)
In recent years, the FDA has approved numerous anti-cancer drugs that are mutation-based for clinical use. These drugs have improved the precision of treatment and reduced adverse effects and side effects. Personalized therapy is a prominent and hot topic of current medicine and also represents the future direction of development. With the continuous advancements in gene sequencing and high-throughput screening, research and development strategies for personalized clinical drugs have developed rapidly. This review elaborates the recent personalized treatment strategies, which include artificial intelligence, multi-omics analysis, chemical proteomics, and computation-aided drug design. These technologies rely on the molecular classification of diseases, the global signaling network within organisms, and new models for all targets, which significantly support the development of personalized medicine. Meanwhile, we summarize chemical drugs, such as lorlatinib, osimertinib, and other natural products, that deliver personalized therapeutic effects based on genetic mutations. This review also highlights potential challenges in interpreting genetic mutations and combining drugs, while providing new ideas for the development of personalized medicine and pharmacogenomics in cancer study.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- Shanghai R&D Centre for Standardization of Chinese Medicines, Shanghai 202103, China.
ORCID profiles: Qingzhong Wang
Funding
- National Natural Science Foundation of China
- Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine
- Shanghai Municipal Health Commission
Cite
APA
Zhou, Y., Peng, S., Wang, H., Cai, X., & Wang, Q. (2024). Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products. Genes, 15(4), 468. https://doi.org/10.3390/genes15040468
Vancouver
Zhou Y, Peng S, Wang H, Cai X, Wang Q. Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products. Genes. 2024;15(4):468. doi:10.3390/genes15040468
BibTeX
@article{Zhou2024,
author = {Zhou, Yalan and Peng, Siqi and Wang, Huizhen and Cai, Xinyin and Wang, Qingzhong},
title = {Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products},
journal = {Genes},
year = {2024},
volume = {15},
number = {4},
pages = {468},
doi = {10.3390/genes15040468}
}
EUVIMED